Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
The University of Edinburgh has developed new methods for cleaning surgical instruments, which completely remove protein contamination, including prions - the infectious agents that cause Creutzfeldt-Jakob Disease (CJD) in humans. More
Two new compounds having HDAC (histone deacetylase) inhibition capability have shown the effect of inducing re-differentiation of human brain and breast cancer cells both in vitro and in vivo. More
High yield and low cost protein production in a few days to a couple of weeks (mg or g of protein). Production of proteins, including antibodies, for High-throughput screening assays, antibody generation and structure-activity analyses. More
The University of Edinburgh has perfected a genetic engineering strategy in mouse embryonic stem cells to replace large regions of mouse chromosomal sequences (>100kb) with the corresponding human syntenic region. More
A number of specific PPLs, a group of prenylflavanone compounds, some novel, were isolated, identified and tested at as low as 0.04 μg/mL to be able to increase survival of neural stem cells, to promote neuronal growth with lengthening of neurite More
Researchers at the University of Edinburgh have identified two protein domains (MBD and CxxC) proven to isolate methylated and non-methylated CpG islands (CGIs), respectively. More
The present invention provides a potent inhibitor of protein glycation and AGEs formation that is particularly advantageous for eye-drop delivery in the prevention and treatment of diabetes- and age-related pathologies. More
Use of depth filters to remove prion infectivity from plasma - derived therapeutic products and/or other biologics. Depth Filtration is a chemically inactive process and therefore does not introduce potentially toxic bi-products or alter components. More
An improved animal restraint jacket designed to protect an implanted vascular catheter or other implanted device in the animal. More
Proprietary manufacturing process for a liquid IVIgG product - in great demand world-wide as one of the principal therapeutics obtained from blood plasma. Process delivers a low IgA content, which increases renal tolerability. More
Your selection
Browse By
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us